Summary
Over roughly one week, five sell-side analysts revised their views on Humana following the insurer's Q2 2026 report, citing the same earnings-led catalyst. The revisions push price targets between $370 and $513 while the stock traded at $364.46. Market commentary centers less on the quarter's headline results and more on a projected multi-year restoration of Medicare Advantage margins culminating in 2028.
The upgrade wave and valuation context
Within 24 hours of Humana's Q2 results (Jul 29, 2026), five firms adjusted their recommendations; Morgan Stanley followed several days later on Aug 4. The firm-by-firm move and the new price targets are:
- Leerink - Outperform - Price Target $513 - Upside vs. Today +40.8%
- BofA Securities - Buy - Price Target $500 - Upside vs. Today +37.2%
- Evercore ISI - Outperform - Price Target $480 - Upside vs. Today +31.7%
- Piper Sandler - Overweight - Price Target $463 - Upside vs. Today +27.0%
- Morgan Stanley - Equalweight - Price Target $370 - Upside vs. Today +1.5%
- Baird - Neutral (maintained) - Price Target $390 - Upside vs. Today +7.0%
InvestingPro's Fair Value sits at $446, implying +22% upside - a midpoint within the range of analyst targets.
Why 2028 is the focal point
Analysts are not celebrating the Q2 print itself. In fact, Humana shares declined roughly 7-9% on the day of the earnings release despite an earnings beat of $7.61 versus a $7.23 consensus. Instead, analysts are looking through near-term volatility toward a specific multi-year recovery path for Medicare Advantage margins. The articulated timeline reads as follows:
- 2026 - Individual Medicare Advantage margins are expected to be below breakeven, with about a 250 basis point Stars-related headwind on the Medical Loss Ratio.
- 2027 - Management targets recovering more than 100 basis points of MA margin while pruning roughly 600,000 members as part of planned exits intended to shed lower-quality growth.
- 2028 - The objective is to reach a sustainable pre-tax Medicare Advantage margin of at least 3 percent; Piper Sandler models EPS of $25.72 for 2028, which equates to a 69 percent compound annual growth rate from 2026 levels.
The Stars rating is the pivotal variable
Central to the recovery scenario are Medicare Advantage Star ratings, because higher Stars ratings unlock bonus payments that can materially improve margins. Management has identified Plan H5216 - which covers about 33 percent of its MA members - as having a credible path back to a 4-Star rating in 2027. Company reporting indicates it is tracking 5 percent ahead on key HEDIS metrics and has improved on 11 of 12 measures versus historical benchmarks. If Star ratings rebound, analysts see a meaningful upside to the bull case.
Counterarguments and lingering concerns
Not all analysts embraced the upgrade narrative. Raymond James downgraded the stock to Market Perform on the same day several firms upgraded, highlighting the Stars decision as a binary event with unresolved unknowns such as cut points and peer performance. They contend the stock, at about 13.5 times their 2028 EPS estimate, may already reflect a substantial amount of favorable outcomes.
Bear-case considerations articulated by skeptics include the risk that rapid 21 percent MA membership growth could attract higher-cost enrollees, that achieving aggressive margin recovery targets demands near-perfect execution, and that changes to policy or risk models could alter outcomes.
What changed in Q2 to prompt the shift
The immediate Q2 catalyst was straightforward: medical costs came in roughly in line with expectations. With year-over-year Medicare Advantage membership growth of about 25 percent, investors had worried that utilization would spike. Instead, the reported medical cost ratio held at 91.2 percent, and inpatient trends showed fewer admissions and lower unit costs. That outcome gave several analysts sufficient confidence to value Humana on a 2028 earnings basis rather than demanding immediate proof of margin improvement.
Structural backdrop
Analysts noting structural demand point to an aging U.S. population supporting secular Medicare Advantage growth. If Humana can execute on the margin recovery roadmap, its scale as a leading pure-play MA insurer is viewed as a potential competitive moat that could underpin durable profitability.
Conclusion
The cluster of upgrades reflects a market narrative that has shifted from short-term results to a specific multi-year earnings and margin recovery thesis anchored on Stars improvements, membership pruning, and in-line cost trends. That narrative has lifted price targets into a wide range, leaving debate over whether the stock already prices in the favorable scenario or still offers room to run.